Thursday Apr 17
ImmunoGen, Inc. Announces Conference Call to Discuss its Third...
ImmunoGen, Inc . , a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 25, 2014, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2014.
Wednesday Sector Leaders: Biotechnology, Rubber & Plastics
In trading on Wednesday, biotechnology shares were relative leaders, up on the day by about 2%.
Wednesday's ETF Movers: FBT, GDX
In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 2.6% on the day.
Immunogen Rating Reiterated by Canaccord Genuity
's stock had its "buy" rating reaffirmed by investment analysts at Canaccord Genuity in a note issued to investors on Wednesday, American Banking and Market News reports.
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
The data were presented at the American Association for Cancer Research Annual Meeting in San Diego, CA.
Immunogen Rating Increased to Outperform at Zacks
The firm currently has a $15.90 target price on the stock. Zacks 's price objective suggests a potential upside of 19.64% from the company's previous close.